SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. The cases seeks to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated i ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - Apple announced an indefinite delay in updates to its Siri digital assistant, affecting features initially promised for June 2024, which led to a significant drop in its stock price [3] - Morgan Stanley analyst Erik Woodring lowered Apple's price target from $275 to $252, citing the delay in Siri features as a factor impacting iPhone upgrade cycles [4] Company Performance - Following the announcement of the Siri update delay, Apple's stock price fell by $11.59 per share, or 4.85%, closing at $227.48 on March 10, 2025 [3] - In the subsequent trading sessions, Apple's stock price further declined by $11.16 per share, or 5.05%, closing at $209.68 on March 13, 2025 [5] - Approximately 50% of iPhone owners who did not upgrade to the iPhone 16 attributed their decision to the delays in Siri feature updates [4]